Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER in adolescent MDD
NCT02431806Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Jun 2015
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (4 arms), sponsored by Forest Laboratories. Primary endpoint: Change From Baseline in Children's Depression Rating Scale-Revised Total Score at 8 weeks. Started Jun 2015; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02431806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431806.